Sir Chris Evans explains why EDX Medical Group (LON:EDX) believes its new workplace health screening service can generate more than £2 million in the current financial year, with employers already discussing programmes covering thousands of staff. He outlines how the company combines rapid on-site sample collection, multi-biomarker testing and personalised health reports to identify risks earlier, reduce disruption and potentially lower the cost of employee ill health.
Key Moments
- 00:19 – Inside EDX Medical’s rapid workplace screening model
- 01:20 – How EDX’s biomarker panels scan for hundreds of conditions
- 02:22 – Why EDX says its service outperforms rivals
- 04:18 – The employer demand behind the £2 million revenue target
- 05:16 – Fresh interest from major employers after launch
- 06:10 – The multibillion-pound cost of workplace ill health
- 07:25 – Why better screening could boost loyalty and productivity
- 07:49 – The follow-up testing strategy EDX has yet to reveal
- 09:02 – The contract and revenue updates investors could see next
EDX Medical Group develops diagnostic products and services designed to detect disease risks earlier and support more personalised healthcare decisions. Its work includes advanced biomarker testing, genomic analysis and digitally supported screening services for individuals, clinicians and employers.
